<DOC>
	<DOC>NCT00565097</DOC>
	<brief_summary>To assess the efficacy of lanreotide in controling total liver volume in patients with polycystic livers this study will be performed. A minimum of 38 patients will be recruited and randomized (1:1) to receive either verum or placebo. Lanreotide is already used in other disease states and found to be safe and non-toxic.</brief_summary>
	<brief_title>Lanreotide as Treatment of Polycystic Livers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
	<mesh_term>Hepatomegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>18 yrsof age Multiple cysts &gt; 20 Cooperating patient Is willing and able to comply with the study drug regimen and all other study requirements Willingness to give written informed consent Use of oral anticonceptives or estrogen suppletion Females who are pregnant or breastfeeding History or other evidence of chronic pulmonary disease associated with functional limitation History of severe cardiac disease History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study Symptomatic gallstones Renal failure requiring hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Polycystic Liver Disease</keyword>
	<keyword>Autosomal Dominant Polycystic Kidney Disease</keyword>
	<keyword>Liver cyst</keyword>
	<keyword>Lanreotide</keyword>
</DOC>